PIK3C3 and neoplasm: This decision was supported by extrapolation from epithelial ovarian cancer protocols, in which bevacizumab has demonstrated clinical benefit, and further justified by the presence of a somatic PIK3C3 mutation in the patient’s tumor, which is associated with PI3K pathway activation and may contribute to angiogenesis.